tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Heron Therapeutics raises FY25 adjusted EBITDA view to $4M-$12M from $0-$8M

Backs FY25 revenue view $153M-$163M, consensus $157.27M

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1